Abstract: Tissue-engineered scaffolds for skin wound healing have undergone tremendous progress since the advent of autologous skin grafts or autografts. The recognition that a three-dimensional (3D) scaffold more closely mimics the biochemical-mechanical milieu of wounds and advancing knowledge of cell biology has led to the next-generation of engineered biopolymeric nanoscaffolds. These can pave the way towards personalized wound care as they can address multiple requirements of skin physiology. A unifying approach is required for translational success of scaffolds, involving clinicians, biologists, and chemists. Following in vitro testing using cell lines, pre-clinical studies on animal models is the next crucial step towards scaffold clinical translation. Often, success noted in these studies does not replicate in human patients due to the heterogeneous nature of wound conditions and causes that cannot be found in a single animal model. In this review, we give an overview of the status of pre-clinical mice models for types 1 and 2 diabetic wound healing and relate this to studies conducted with polymeric nanoscaffolds. Translational shortcomings of these models are analyzed where they fail to provide a good replica of human conditions. Categorization and use of more sophisticated models, which can closely mimic the diabetic features, are addressed for translational use of nanoscaffolds.
Introduction
Translational wound healing research is faced with the difficulty of having to address the heterogeneous nature of wounds, more so, in the case of chronic wounds such as diabetic foot ulcers (DFUs) and pressure ulcers, which often have an unexpected sequence of events [1] . Clinicians are faced with challenges such as age of patients, hormone levels, microbiota, and the various causes of wounds. The available wound care options do not necessarily categorize patients according to clinical requirements, and this is where reverse translational strategies become important to explore wound healing matrices. Developing and adapting animal models appropriate to the diversity of clinical setting become crucial. Many criticisms about animal models in pre-clinical research have been raised due to failure to translate to patients. The advent of new treatment in wound healing such as polymeric nanofiber scaffolds further demands carefully chosen models for translational success. In this context, electrospinning is considered as an efficient method for fabricating biomimicking polymeric fibers with tunable fiber diameters [2] . It also offers the possibility of developing multifunctional formulations via the combination of fibers with nanocarriers such as micelles, nanoparticles (NPs), etc., which, in turn, allows sustained release of drugs/growth factors to enhance tissue repair.
Extreme loss of skin function and structure due to burns, injury, or illness exposes the body to a risk of systemic infection and can cause significant physiological imbalance, which may eventually become life threatening [3] . Indeed, the skin forms an important physical and chemical interface protecting the host against dehydration, toxins, and invading microorganisms [4] . The standard clinical procedure for the treatment of large full-thickness skin defects is autologous skin grafts or autografts, which are obtained from the patients, themselves [5, 6] . However, autografts are limited and often lead to scarring in patients [7, 8] . Skin harvested from other individuals, i.e. allografts present several ethical problems and are influenced by availability and potential disease transmission [7] . During the past few years, progress in the field of tissue engineering has led to the design and commercialization of several tissue-engineered products for skin regeneration. The latter may be classified according to the anatomical structure to be regenerated, namely, epidermal, dermal, or dermal/ epidermal (or composite) substitutes. Epidermal skin substitutes available for clinical applications may consist of cells of either autologous or allogenic origin, for example, Epicel ® (Genzyme Biosurgery, USA) or MySkin ® (CellTran Ltd, UK), respectively [9] . However, despite efficient epidermal coverage, autologous and allogenic epidermal substitutes result in poor attachment rates, which, in turn, lead to blister formation [10] . The lack of dermal tissue in full thickness wounds and the poor quality of scars following treatment with autografts led to the development of dermal substitutes such as Dermagraft ® (Shire Regenerative Medicine, Inc, USA), Integra™ (Integra LifeSciences, USA), Karoderm™ (Karocell Tissue Engineering AB company, Sweden), etc. [11] . In an attempt to mimic the skin layers (dermis and epidermis) within the same construct, dermal/ epidermal substitutes were fabricated, for instance, PermaDerm ® (Regenicin Inc., USA) and Apligraf ® (Novartis, USA). Despite enormous progress achieved on TE-based skin substitutes, several challenges still need to be overcome to achieve the optimal skin substitute, in particular, improved adhesion of cultured keratinocytes to the wound bed, enhanced rate of neovascularization of tissue-engineered skin, and better resistance of scaffolds materials towards wound contraction and fibrosis [5, 12, 13] . These drawbacks have opened avenues for designing advanced skin substitutes, which involve combining scaffolds, cells, and growth factors. Nanostructured scaffolds provide numerous advantages, such as three-dimensional (3D) micro environment, tailored mechanical and biological properties. Nano-engineered biomaterials in the form of NPs, nanofibers, or a combination of both have been designed for skin regeneration [4] . These scaffolds often perform well during the classical in vitro tests using cell lines such as fibroblasts, keratinocytes, among others. Subsequent in vivo experiments are often carried out on a chosen animal model to address one specific problem such as impaired wound healing in diabetic patients. A single in vivo model is, therefore, very often not suitable to conclude on the performance of the scaffold as most animal models do not replicate the human physiological conditions closely.
In this review, we outline current diabetic animal models used for in vivo testing of polymeric scaffolds and suggest ways to come up with avenues to correlate polymeric scaffold performance with in vivo models, which can facilitate both reverse translation and translational research. We point out that a synergy is required between polymer experts, biologists, and clinicians.
Skin: physiology and regeneration
The skin consists mainly of two morphologically distinct layers, namely, the epidermis and the dermis. The epidermis, which is the top thin avascular layer (0.1-0.2 mm in depth and nourished through diffusion from the dermis), comprises mainly of a self-renewing population of keratinocytes and is critical for survival as it acts as a barrier protecting the body against exogenous substances, chemicals, pathogens, and prevents dehydration through the regulation of fluid loss [14] . Underlying the epidermis is the dermis, which is a thicker vascularized layer (approx. 2 mm) of connective tissues consisting mainly of extracellular matrix (ECM), structural components such as collagen and elastin, and a vascular network [15, 16] . The nanoscale fibrillar ECM network is highly dynamic and plays an important role in hydration and in maintaining moisture levels. It also has a prominent role in directing cellular behavior through direct and indirect signaling [9] . Cells including fibroblasts, endothelial cells, smooth muscle cells, and mast cells are interdispersed within the ECM [15] . The epidermis is securely attached to the collagen fibers of the dermis by the complex basement membrane (BM) [17] . A collection of adhesion receptors extends through the BM and acts as anchoring filaments binding keratinocytes from the epidermis to the lower BM. Epidermal/dermal communication across various levels are essential to establish, maintain, or restore tissue homeostasis. Following skin damage from burns, contusions, hematomas, or diseases, a consecutive cascade of events, i.e. wound healing takes place to restore the skin structure and function [18] . The wound healing process is characterized by three different phases, namely, inflammation, proliferation, and remodeling, which occur sequentially following skin damage [18] . Disruption of the epidermal layer immediately triggers keratinocytes and platelets to release cytokines like interleukins leading to the activation of the blood clotting cascade.
The release of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) by platelets stimulate the proliferation of endothelial cells initiating angiogenesis, which is crucial for the synthesis, deposition, and organization of a new ECM [19] . The presence of growth factors TGF-β1 and platelet-derived growth factor (PDGF) attracts fibroblasts into the wound site as well as initiates phenotypic changes in these cells converting fibroblasts into myofibroblasts. These cells then secrete large amounts of ECM and align themselves along the borders of the wound to generate a constrictive force, facilitating wound closure [20] . Fibroblasts in the wound site then secrete a wide range of molecules including growth factors and ECM proteins like VEGF, dermatopontin (DPT), and collagen that regulate the proliferation and migration of fibroblasts, keratinocytes, and endothelial cells [21] .
The next phases, namely, migration and proliferation, are interdependent [18, 22] . Migration is characterized by infiltration of new epithelial cells into the damaged area to replace dead cells. The proliferation phase involves simultaneous movement of fibroblasts and endothelial cells to the damaged area forming a granular tissue composed of a new matrix and blood vessels [23] .
The last phase, maturation, comprises the remodeling process, during which fibroblasts cover the damaged skin surface with a new skin layer and ideally leaving no evidence of scar [1] . In the final remodeling phase of wound healing, a network of collagen and elastin fibers, together with proteoglycans and glycoproteins, replaces the granulation tissue and initiates the maintenance of balance between matrix production and degradation [4] .
Skin substitutes

Skin defects and wounds
Depending on the depth of the skin defect, different measures need to be taken. Injuries involving the epidermis, as well as those extending into the superficial layer of the dermis (partial thickness injuries), will heal naturally without surgical intervention, provided that there are sufficient keratinocyte stem cells present in the remaining epidermis or in the residual dermis [24] . However, if this is not the case, then, skin regeneration may be achieved using epithelial stem cells derived from hair follicles and/ or sweat glands [24] . Defects extending into the deeper dermis require a more complex treatment, due to the absence of keratinocyte stem cells. The "gold standard" approach for the treatment of such wounds is to apply split-thickness skin grafts (taken from elsewhere in the body) that contain all epidermal and marginal parts of the dermis, thereby, transferring self-renewing keratinocyte stem cells to the affected area. However, if the wound injury is extensive, it is often necessary to "build up" the skin in two stages whereby one material is used to provide a dermal equivalent, which must become vascularized before an epidermal material (most often a very thin splitthickness graft, but occasionally cultured cells or tissueengineered skin) may be placed on top [14] .
Scarring or wound contraction is a crucial hallmark of skin reconstitution [24] . The body must produce new collagen fibers to close the wound. However, the body cannot rebuild the tissue exactly as it was, and thus, the new (scar) tissue has a distinct collagen pattern and a different skin texture (and quality) than the surrounding normal skin.
Overall, successful skin reconstruction with skin substitutes depends on the presence of self-renewing keratinocyte stem cells for re-epithelialization and a functional dermal substitute consisting of the appropriate cellular and acellular components that allow no or only limited scarring of the developing skin [24] .
Commercially available skin substitutes
Skin substitutes refer to wound coverage materials that help in would closure and replace the functions of the skin, either temporarily or permanently, depending on the product characteristics [25] . The ideal substitute should allow immediate replacement of both the lost dermis and epidermis, and should be permanent. In addition, it should be cost effective, have a long shelf-life and easy storage conditions, durable with long-term wound stability, allow easy handling and application, and be able to withstand the shear forces and infection [26] .
Temporary skin substitutes provide transient physiologic wound closure, with protection from mechanical trauma, and act as a physical barrier to bacteria and create a moist wound environment. Such substitutes are used to facilitate epithelialization and control pain, as dressing on clean superficial wounds until epithelialization, and to provide temporary physiological closure of deep wounds after excision while awaiting autografting [26] . Permanent substitutes, on the other hand, achieve permanent wound closure. Skin substitutes may be cellular autogeneic (cells derived from the patient), cellular allogeneic, or acellular (deprived of cells). Several skin substitutes are available on the market for epidermal, dermal, or epidermal/ dermal replacement, and each has advantages and limitations [27, 28] . Tissue-engineered skin refers to a material made up of cells, ECM, or a combination of both. Most of the commercially available skin substitutes provide only temporary coverage of skin surfaces and need to be replaced later. An extensive review of skin substitutes has been described by Debels et al. [29] .
In vivo models for diabetic ulcers
Despite the availability of a number of skin replacement options, there is no ideal skin substitute available, to date, that meets all the required criteria of the wound healing process in humans. Indeed, the design of a bioengineered skin replicating the essential physiological characteristics for replacing diseased or damaged parts remains a real challenge. Current efforts are being focused on the fabrication of biodegradable and biocompatible nanomaterials that structurally and functionally mimic the natural skin environment. As discussed in several reviews, various nanotherapeutic approaches are being investigated for wound healing, in particular, NPs and scaffolds, which target the main phases of wound repair (inflammation, remodeling, and wound contraction) [30] [31] [32] [33] [34] . Before being tested clinically, these materials have to be tested in vitro and, more importantly, in vivo such that the outcome on humans may be better predicted. As a result, appropriate animal models need to be selected depending on the wound healing situation being investigated. Animal models need to mimic, as closely as possible, the physiological conditions and characteristics of healthy or diseased wounds as in humans. Hence, wise and careful choice of suitable animal models is a top priority for proper data interpretation. In this section, the benefits and limitations of current animal-based models will be discussed with particular highlight on the urgent need for improved predictive pre-clinical models for wound healing research.
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. There are two main types of diabetes, namely, type 1 diabetes and type 2 diabetes. Type 1 diabetes is due to an autoimmune destruction of the insulin-producing pancreatic β cells, and type 2 diabetes, which is the most common type, is caused by insulin resistance coupled by a failure of the β cell to compensate [35] . Diabetes is a major worldwide health problem, and according to WHO, there were 422 million people suffering from diabetes in 2014 [36] . A major complication of diabetes is impaired healing, which often leads to chronic wounds and limb amputation [37] . DFUs are the leading cause of non-traumatic lower limb amputations [38] . WHO projects that diabetes will be the seventh leading cause of death by 2030 [39] . Factors contributing to wound healing deficiency in diabetic patients include altered host response, diminished antibacterial defenses, prolonged inflammation, altered protease activity, a tendency for vascular abnormalities, the generation of an inadequate number of cells to accomplish rapid and robust healing, decreased growth factor production, inability to form a sufficient amount of ECM, and alterations in apoptosis [40, 41] .
The main differences in the wound healing process of healthy individuals and those suffering from diabetes are depicted in Figure 1 . The acute wound healing process in healthy persons is guided and maintained through integration of multiple signals in the form of cytokines and chemokines released by a wide range of cells including keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. During wound-induced hypoxia, VEGF released by macrophages, fibroblasts, and epithelial cells induces the phosphorylation and activation of eNOS in the bone marrow, leading to an increase in NO levels, which, in turn, triggers the mobilization of bone marrow endothelial progenitor cells (EPCs) to the circulation. The chemokine SDF-1α promotes the homing of these EPCs to the wound site, where they participate in neovasculogenesis. On the other hand, in diabetic patients (Figure 1, right) , endothelial nitric oxide synthase (eNOS) phosphorylation in the bone marrow is impaired, which directly limits the mobilization of EPCs from the bone marrow into the circulation [42] . SDF-1α expression in epithelial cells and myofibroblasts is decreased in the diabetic wound, which prevents EPC homing to wounds, thereby, resulting in impaired wound healing.
In diabetes, the different phases of wound healing do not occur in synchrony, due to the complications of the disease. The pathophysiology of diabetes-related wound healing problems is complex and poorly understood. The use of animal models has provided valuable insights into the pathogenesis of both diabetes and chronic wounds. Indeed, the wound healing potential may be quantified by the analyses of re-epithelialization, granulation tissue formation, and blood vessel density, as well as VEGF and inflammatory response measurements. However, there are only a few published reports, to date, whereby the wound healing differences among differing diabetic animal models have been investigated. Most of the available models are based on rodents due to their small size, short generation time, easy availability, and economic considerations [35] . These models, thus, do not necessarily replicate the human conditions.
Animal models for type I diabetes
Animal models for type 1 diabetes range from animals with spontaneously developing autoimmune diabetes to chemical ablation of the pancreatic β cells [35] . The most commonly used models of type 1 diabetes and their limitations are outlined in Scheme 1. The non-existence of standard protocols, different mechanism of diabetes development in human vs. animal models, and the possibility of reversible diabetes are some of the problems identified in these models.
In chemically induced models of diabetes, a high percentage of the endogenous β cells are destroyed using cytotoxic glucose analogs such as streptozotocin (STZ) or alloxan (ALX), and thus, there is little endogenous insulin production, leading to hyperglycemia and weight loss. This method is versatile and can be used to induce type 1 or type 2 diabetes [43, 72] . STZ [2-deoxy-2-(3-(methyl-3-nitrosoureido)-d-glucopyranose] is synthesized by Streptomycetes achromogenes. It enters the pancreatic β cell through the Glut-2 glucose transporter after i.p. or i.v. injections and causes alkylation of the DNA [44] , which, in turn, activates PARP leading to NAD+ depletion, a reduction in cellular ATP, and subsequent inhibition of insulin production [45] . On the other hand, ALX (2,4,5,6-tetraoxypyrimidine; 5,6-dioxyuracil) generates the reactive oxygen species (ROS) in a cyclic redox reaction with its reduction product, which contributes to DNA damage and eventually cell death [46] . STZ may be administered as a single high dose or as multiple low doses, and the dose can vary greatly depending on the animal gender and strain. Multiple low-dose STZs have been most currently used for wound healing studies involving polymeric scaffolds (Table 1 ). An analysis of the results obtained indicates that translation from mice to humans faces many barriers apart from the fact that the skin of mice is physiologically, morphologically, and functionally different from the human skin. Diabetic wounds are usually classified using a wound classification system. However, there are various classification systems which are in use, the Wagner's and University of Texas being the two well-established ones [73] . Wagner used wound depth, and the University of Texas added infection and ischemia as the two other principal factors to be taken into consideration. These factors are heterogeneous and vary according to patient. Mice studies do not necessarily make use of this classification to mimic the diabetic wound condition. Adding this parameter would enhance translational capacity of polymeric scaffolds.
Animal models for type 2 diabetes
Type 2 diabetes is modeled in both obese and non-obese animal models with varying degrees of insulin resistance and β-cell failure [35] . Most of the type 2 diabetes animal models are obese, reflecting the human condition where obesity is closely linked to type 2 diabetes development. Some of the most commonly used models of type 2 diabetes and their shortcomings for translation are outlined in Scheme 2. Problems such as generation of the model, correct human replication, and difference between male and female mice have been identified.
Spontaneous or genetically derived diabetic animals
Monogenic obese models
Monogenic obese diabetic animal models are commonly used in research despite the fact that obesity in humans is rarely caused by a monogenic mutation. The most widely used monogenic models of obesity are defective in leptin signaling. Leptin induces satiety, and thus, a lack of functional leptin results in hyperphagia and subsequent obesity. Examples of such models include the Lep ob/ob mouse, which is deficient in leptin, and the Lepr db/db mouse and the Zucker diabetic fatty (ZDF) rat, which are deficient in the leptin receptor. However, the usage of these diabetic models are significantly limited [93, 94] as leptin plays an important role during wound healing, and therefore, the healing process of these genemodified mice may be interfered by the mutation of leptin and/or the leptin receptor [95] .
-Lep ob/ob mouse The Lep ob/ob mouse is a model of severe obesity. Their weight starts to increase at 2 weeks of age, and the animals develop hyperinsulinemia. Hyperglycemia becomes apparent by 4 weeks of age, with blood glucose concentrations continuing to rise, and peaking at 3-5 months, after which, they drop as the mouse becomes older [96] . These mice display other metabolic aberrations such as hyperlipidemia, a disturbance in temperature regulation, lower physical activity [96] , and infertility [97] . Although there are some abnormalities in insulin release [98] , the pancreatic islets maintain insulin secretion. The lack of complete β-cell failure in this model indicates that diabetes is not severe, and therefore, this model is not completely representative of human type 2 diabetes.
-Lepr db/db mice This model is due to an autosomal recessive mutation in the leptin receptor [99] . These animals are obese, hyperphagic, hyperinsulinemic, and hyperglycemic. Obesity is apparent from 3 to 4 weeks of age with hyperinsulinemia becoming evident at around 2 weeks of age and hyperglycemia developing at 4-8 weeks. These mice models develop ketosis after a few months of age and have a relative short lifespan [49] .
-Zucker fatty rats and Zucker diabetic fatty (ZDF) rats These animals have a mutated leptin receptor [100] that causes hyperphagia. The rats become obese at around 4 weeks of age. These rats also show hyperinsulinemia, hyperlipidemia, hypertensivity, and have impaired glucose tolerance [49] .
Polygenic obese models
Polygenic models of obesity may provide a more accurate model of the human condition. However, unlike the monogenic models, there are no wild-type controls. In addition, the male sex bias is more extreme in these models [101] .
-KK mice KK mice are mildly obese, and they develop severe hyperinsulinemia, demonstrate insulin resistance in both muscle and adipose tissue, and show signs of diabetic nephropathy. The pancreatic islets in these animal models are hypertrophic, and the β cells are degranulated [102] .
-OLETF rats OLETF rats display mild obesity and late-onset hyperglycemia (after 18 weeks), with males only suffering from diabetes. Three stages of histological changes are noted in the pancreatic islets. First, cellular infiltration and degeneration is seen when the animals are between 6 and 20 weeks old. This is followed by a stage of hyperplasia between 20 and 40 weeks. In the final stage, the islets become fibrotic and are replaced by connective tissue [103] . These rats also exhibit renal complications [104] .
-New Zealand obese (NZO) mice
These animals are hyperphagic and obese, which may be a consequence of leptin resistance [105] . About 50% of the males develop diabetes [106] . The islets are hyperplastic and hypertrophic at 3-6 months of age. However, β-cell loss occurs later, and there are signs of latent autoimmune diabetes in adults [107] .
-TallyHo/Jng mice In these mice, adiposity is increased, and plasma triglycerides, cholesterol, and free fatty acid levels are elevated. Only male mice show hyperglycemia, which develops as early as between 10 and 14 weeks of age. The pancreatic islets are hypertrophied and degranulated, and hyperinsulinemia is evident. The TallyHo mouse has not yet been completely characterized for diabetic complications [101] , although a recent study has used this model to study diabetic wound healing [108] .
-NoncNZO10/LtJ mice These obese mice develop liver and skeletal muscle insulin resistance at 8 weeks and chronic hyperglycemia from about 12 weeks [101] . Diabetic nephropathy has been observed in some males aged about 1 year [101] . This model has been suggested to be suitable for studies in diabetic wound healing [109] .
Non-obese models
Non-obese models include models that have β-cell inadequacy, which is what ultimately leads to type 2 diabetes in humans [110] .
-Goto-Kakizaki rats This is a lean model of type 2 diabetes, which is characterized by glucose intolerance and defective glucoseinduced insulin secretion. The β-cell mass and functions are abnormal [111, 112] . However, islet morphology and metabolism seem to differ between differing colonies of these rats.
Diet/Nutrition-induced diabetic animals
In these models, normal chow (on a caloric basis usually around 26% protein, 63% carbohydrate, and 11% fat) is exchanged for a diet where the number of calories from fat is substantially increased (around 58% of energy derived from fat). Indeed, high-fat feeding leads to obesity, hyperinsulinemia, and altered glucose homeostasis due to insufficient compensation by the islets [113] . The weight gain is associated with insulin resistance and the lack of β-cell compensation. Nutrition-induced diabetes is often used in transgenic or knock-out models, which may not show an overt diabetic phenotype under normal conditions.
Surgical diabetic models
This method consists of complete or partial pancreatectomy in animals. Partial pancreatectomy in animals performed as 70% or 90% dissection of the pancreas has been reported in various animal species mostly in dogs, pigs, rabbit, and also rats [114, 115] . It does not cause severe form of diabetes and is characterized by moderate hyperglycemia.
Compared to type I diabetes, very few in vivo studies with polymeric scaffolds have used animal models to investigate type 2 diabetes ( Table 2 ). The db/db mouse seems to be able to mimic the human condition more -Compared to the models used, the db/db mouse has a reduced number of epidermal nerves, which is similar to humans with diabetes -db/db mouse was shown to have a comparable overexpression of neutral endopeptidase (NEP) to that seen in diabetic patients [118, 119] Male diabetic BKS.Cg-m +/+ Lepr, db/db mice [120] -Lepr db/db mice Dextrin-rhEGF conjugate [122] -At day 16, no significant differences in neo-dermal tissue formation were apparent between the dextrin conjugate groups and untreated controls -Significant reduction in wound area -Increased wound re-epithelialization -Significant increase in angiogenesis -This strain heals wounds primarily by the formation of granulation tissue rather than by contraction [123] closely. These studies most commonly looked at wound closure as the measurable outcome. Depending on the nature of scaffold and added molecule/growth factor, other parameters were then considered such as recruitment of macrophage or fibroblasts. In general, in vivo studies conducted using type 1 and type 2 diabetes models investigated the wound closure rates, re-epithelialization, organization of collagen fibers in the granulation tissue, and neovascularization. Investigations regarding the formation of skin appendages such as hair follicles were also made in type 1 diabetes models. However, the classification of wounds was also not addressed in type 2 models. In a study carried out on the implementation of a DFU classification system for research purposes to predict lower extremity amputation in type 2 diabetic patients, it was found that wound diameters and the surface area were not significantly associated with any type of amputation [127] . However, a significant association was found between the major lower extreme amputation and limb ischemia.
Minor toe amputation was associated with deep wounds and those with grades 3 and 4 sepsis. Neuropathy was associated with both minor and major amputations. This study used the wound classification adopted by the International Consensus for the Diabetic. These criteria were the degree of limb ischemia, sensory neuropathy, depth and surface area of the wound, severity of sepsis, and ESRF (end-stage renal disease). Thus, it becomes important to evaluate polymeric scaffolds taking into consideration a system of wound classification.
Recommendations
Polymeric scaffolds offer the possibility to move toward personalized medicine. ketosis. In addition, while the vast majority of wounds are made on mouse trunk (dorsal) skin, healing progression varies depending on the species and body site. Models used, so far, are not completely representative of human type 2 diabetes given that diabetes development including pre-diabetic state, pathophysiology, and comorbidities are drastically different in these models compared with human disease, resulting in the lack of model translatability. A key feature of human diabetes is an intact leptin pathway; however, the most commonly used rat and mouse models feature monogenic mutations in either the leptin receptor (ZDF rat, db/db mouse) or the leptin molecule (ob/ob mouse). Diet-induced models with an intact leptin pathway rely on high-fat diets to induce diabetes, and result in models lacking key disease features such as hyperglycemia. Importantly, many current rodent models, including the ZDF rat, also lack the pre-diabetic state observed in human disease [126] . Indeed, the diabetic wound models described in this review are far from ideal and only represent the best available at present. Clearly, the best is yet to come. Until then, coupling together two or more existing impaired wound healing models in a combinatorial approach may offer an improved prediction of the human state. Ninety percent of type 2 diabetics are overweight or obese. Thus, coupling the different strains Lep ob and Lepr db mice for type 2 diabetes, which can mimic different complications associated with diabetes and the use of new models such as TallyHo/JngJ mice polygenic model for obesity and diabetes, are new avenues to test the performance of polymeric scaffolds. The two novel polygenic mouse models of type 2 diabetes, TallyHo/JngJ and NONcNZO10/LtJ, contrast with C57BLKS/J-Leprdb (db/ db) monogenic diabesity model as they are believed to be more representative of the obesity underlying human type 2 diabetes.
The ZDSD rat, recently developed by crossing the lean ZDF rat to an obesity-prone Sprague-Dawley (SD) rat with polygenic obesity, is believed to be the most translatable diabetes rodent model (Figure 2) . This model has an intact leptin pathway and progressively develops many human-like features of diabetes and metabolic syndrome while on a normal chow diet. Insulin resistance and β-cell failure are observed in the ZDSD rat, in a manner similar to the human disease. Furthermore, insulin resistance persists across the pre-diabetic and diabetic states in both ZDSD rats and humans, in contrast to currently available rodent models, e.g. the ZDF rat, where β-cell failure is observed at a much earlier time frame [128] .
Reverse translation identifying the causes of treatment failure is crucial in diabetic wound healing and would allow the engineering of more adapted scaffolds and use of proper multi pre-clinical animal models as well as shed light on the molecular mechanism of wound healing. These factors will open up the possibility to categorize available skin substitutes as well as new nanoscaffold treatments according to the patients' conditions and, thus, enhance success rate.
Conclusions
The improvement of diabetic wound healing still represents a major clinical challenge to researchers. The challenge faced is to identify a suitable animal model that best represents the human situation. However, the majority of diabetic wound healing models are in rodents and are hindered by rapid contraction and, thus, do not reflect epithelial cell migration, as seen in the human wound [129] . Confusingly, the observed wound repair phenotype differs between the diabetic models described and the wound type employed [130, 131] , complicating the prediction of the human clinical state. Hence, ideally, more than one animal model should be used to represent the diversity seen in human diabetic patients. A synergy is required between clinicians, biologists, and biomedical engineer/polymer chemists for the success of polymeric scaffolds. Archana Bhaw-Luximon holds a PhD in Polymer Chemistry and is currently an Associate Professor and Unit Leader of the Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research. The research thrusts of her Unit are design of polymeric biomaterials for fabrication of scaffolds for skin and bone tissue regeneration, engineering nanocarriers for anti-cancer and anti-diabetic drugs/biomolecules, and exploitation of materials from land and marine resources such as sugarcane bagasse and seaweeds for high-end applications.
Bionotes Nowsheen Goonoo
